Releases Details

MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options, PDMR dealing and Total Voting Rights

Gaithersburg, Maryland - 3 May 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 31 March 2023 and 12 April 2023, as per filings lodged with the SEC, Doug Doerfler, Chief Executive Officer, exercised options over 60,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 60,000 new shares of Common Stock issued pursuant to the Exercise, were sold by Doug Doerfler at a price range between of $5.00 and $5.03 per Common Stock ("Sale"). The sold shares represent approximately 1.6% of Doug Doerfler's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Doug Doerfler holds 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company. Following the Exercise, Doug Doerfler holds a further 3,293,680 options over Common Stock.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Doug Doug Doerfler on 18 November 2022 relating solely to the sale of shares acquired from exercise of an option that expires on 11 November 2024.

Additionally, the Company issued a further 86,154 of Common Stock to non-PDMR's pursuant to its block admission facility in satisfaction of the exercise of share options.

Total voting rights

The 146,154 new Common Stock have been admitted to trading on AIM pursuant to the Company's existing block admission facility. The new Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the above will be 103,050,899 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

MaxCyte Contacts:

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM